Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

Table 4 Univariate and multivariate analysis of clinicopathological factors associated with OS

Variables	5-year OS rate (%)	Univariate P-value	Multivariate analysis
Variables	5-year OS rate (%)	Univariate P-value	HR (95% CI)	P-value
< Patient’s factor >
Age (< 70 years / ≥70 years)	79.8 / 78.5	0.56
Sex (men/women)	84.4 / 65.4	0.08
< Pre-CRT factor >
Stage (I, II/III)	80.1 / 78.6	0.95
Main tumor location (Ra/Rb, P)	83.3 / 78.6	0.80
< Treatment factor >
Drug (S-1/UFT)^a	76.7 / 93.3	0.21
Surgical procedure (LAR/ others)	89.2 / 70.9	0.01	5.03 (1.39–18.13)	0.04
< Post-CRT factor >
Tumor differentiation (diff./undiff.)	78.6 /85.7	0.72
fStage (I,II/III)**	89.4 / 56.6	0.003^b
T (1,2/3,4)	80.1 / /78.4	0.37
Lymph node metastasis (−/+)	89.9 / 51.5	< 0.001	3.26 (1.05–10.10)	0.04
Venous invasion (−/+)	84.3 / 73.5	0.28
Lymphatic invasion (−/+)	87.8 / 58.1	0.002	4.97 (1.37–18.04)	0.01
IDO (−: +)	85.4 / 64.8	0.02	7.10 (2.31–21.81)	0.0006
PD-L1 (−: +)	86.5 / 70.6	0.02	2.23 (0.81–6.12)	0.12
Pathological response (Non-responder /Responder)	89.5 / 73.5	0.03	1.28 (0.31–5.26)	0.73

OS Over-all survival, CRT Chemoradiotherapy, Ra Upper rectum, Rb Lower rectum, P Anal canal, diff./undiff. differentiated histological type/undifferentiated histological type, IDO Indoleamine-pyrrole 2,3-dioxygenase, PD-L1 programmed death-ligand 1, fStage Final pathological stage, HR Hazard ratio, CI Confidence interval
^aOne patient who used 5-FU for CRT was excluded
^bFinal stage was excluded from multivariate analysis because it was confounder of lymph node metastasis

ISSN: 1471-2407